PMV Pharmaceuticals
PMVP
51 hedge funds and large institutions have $1.1B invested in PMV Pharmaceuticals in 2020 Q3 according to their latest regulatory filings, with 51 funds opening new positions, increasing their positions, reducing their positions, and closing their positions.
72.59% more ownership
Funds ownership: 0% → 72.59% (+73%)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
O
OrbiMed
New York
|
+$270M |
| 2 |
IVM
InterWest Venture Management
San Francisco,
California
|
+$238M |
| 3 |
Viking Global Investors
Stamford,
Connecticut
|
+$97.2M |
| 4 |
BC
Boxer Capital
San Diego,
California
|
+$83.5M |
| 5 |
ACA
Avoro Capital Advisors
New York
|
+$68.1M |
Top Sellers
PMVP Hedge Fund Activity: Q3 2020 in Review
51 of the 4,971 institutional investors tracked by Wall St. Rank reported a position in PMV Pharmaceuticals (PMVP) for Q3 2020, worth a combined $1.1B.
Buyers outnumbered sellers: 51 funds opened new PMVP positions and 0 closed out — a net gain of 51 holders — while 0 added to existing stakes and 0 trimmed.
The largest buyer was OrbiMed, opening a new position worth an estimated $270M.
- 51 institutional investors held PMV Pharmaceuticals (PMVP) as of Q3 2020, up from 0 in Q2 2020.
- Funds reported $1.1B of PMV Pharmaceuticals stock for Q3 2020.
- 51 funds opened new PMV Pharmaceuticals positions in Q3 2020 and 0 closed out, a net change of +51 holders.
- The largest PMV Pharmaceuticals buyer in Q3 2020 was OrbiMed, an estimated $270M added.
Based on aggregated 13F filings for Q3 2020.